Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Orphazyme A/S: Stabilisation measures taken

Orphazyme A/S
Posted on: 24 Nov 17
Company announcement
No. 15/2017
Orphazyme A/S

 

Ole Maaløes Vej 3
DK-2200 Copenhagen N

 

www.orphazyme.com
Company Registration No. 32266355

 

5 December 2017

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

This announcement does not constitute an offering circular and nothing herein contains an offering of securities.

With reference to the company announcement no. 7/2017 dated 16 November 2017 regarding the beginning of the stabilisation period following the initial public offering and admission to trading and official listing of the temporary purchase certificates and the shares of Orphazyme A/S ("Orphazyme") on Nasdaq Copenhagen (the "Offering" or the "IPO"), Orphazyme has received notification that Danske Bank, acting as stabilising manager in the Offering, has taken stabilisation measures between 27 November 2017 and 5 December 2017 as set out in the attached notification with respect to the shares of Orphazyme.

For additional information, please contact

Orphazyme  
Anders Hinsby, CEO+45 31 44 31 39
Impact Partners  
Michael Steen-Knudsen+45 25 17 18 15

Important notice

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Orphazyme A/S ("Orphazyme" or the "Company") in any jurisdiction where such offer or sale would be unlawful and the announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdictions, including but not limited to, the United States, Australia, Canada and Japan.

This announcement does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States absent registration or to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make any offering of the securities in the United States.

In any member state of the European Economic Area ("EEA Member State"), other than Denmark, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the "Prospectus Directive"), this communication is only addressed to and is only directed at investors in that EEA Member State who fulfil the criteria for exemption from the obligation to publish an offering memorandum, including qualified investors, within the meaning of the Prospectus Directive as implemented in each such EEA Member State.

This announcement is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities falling within Article 49(2)(a) - (d) of the Order (the persons described in (i) through (iii) above together being referred to as "relevant persons").  The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons.  Any person who is not a relevant person should not act or rely on this document or any of its contents.

In connection with the offering, Danske Bank A/S (the "Stabilising Manager") (or persons acting on behalf of the Stabilising Manager) may over-allot securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager (or persons acting on behalf of the Stabilising Manager) will undertake stabilisation. Any stabilisation action may begin on or after the date of commencement of trading and official listing of the securities on Nasdaq Copenhagen A/S and, if begun, may be ended at any time, but it must end no later than 30 days after the date of commencement of trading and official listing of the securities.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as "believe", "expect", "anticipate", "intends", "estimate", "will", "may", "continue", "should", and similar expressions. The forward-looking statements in this announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

5 December 2017

Orphazyme A/S (ticker: ORPHA) (the "Company")

Mid-Stabilisation Period Notice

Further to the pre-stabilisation period announcement dated 16 November 2017, Danske Bank A/S (Niels Erik Nielsen, telephone +44 (0)20 7410 8070) hereby gives notice that the Stabilisation Manager named below undertook stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) in relation to the offer of the following securities, as set out below;

The securities:
Issuer: Orphazyme A/S
Securities:Ordinary shares (DK0060910917)
Offering size:8,625,000 shares of DKK 1 nominal value each
Offer price:DKK 80 per share
Market:Nasdaq Copenhagen (XCSE)
Ticker:ORPHA (ordinary shares)
 
Stabilisation Manager: Danske Bank A/S
Holmens Kanal 1-12
1092 København K
Denmark
Maximum size of over-allotment facility:Up to 1,125,000 shares

Summary of daily stabilisation transactions

Date Price
(lowest)
Price (highest) Price (weighted average) Quantity Currency Market
27 Nov 201772.075.573.054720,600DKKNasdaq Copenhagen
28 Nov 201773.575.074.50003,000DKKNasdaq Copenhagen
29 Nov 201774.075.575.09755,000DKKNasdaq Copenhagen
30 Nov 201774.075.574.76586,000DKKNasdaq Copenhagen
1 Dec 201774.576.075.29934,000DKKNasdaq Copenhagen
4 Dec 201775.077.076.16934,000DKKNasdaq Copenhagen
5 Dec 201775.577.075.93293,608DKKNasdaq Copenhagen
Stabilisation measures taken


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Orphazyme A/S via GlobeNewswire
HUG#2154206
GlobeNewswire
globenewswire.com

Last updated on: 06/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.